Hepcidin as a new biomarker for detecting autologous blood transfusion
Autor: | Neil Robinson, Nicolas Leuenberger, Niels Lion, Martial Saugy, Raul Nicoli, Jean-Daniel Tissot, Stefano Barelli, Laura Barras, Norbert Baume |
---|---|
Rok vydání: | 2016 |
Předmět: |
medicine.medical_specialty
Blood transfusion biology business.industry medicine.medical_treatment 010401 analytical chemistry Autologous blood Inflammation Hematology 030204 cardiovascular system & hematology 01 natural sciences Gastroenterology Blood proteins 0104 chemical sciences Clinical trial 03 medical and health sciences 0302 clinical medicine Hepcidin Internal medicine medicine biology.protein Biomarker (medicine) medicine.symptom Prospective cohort study business |
Zdroj: | American Journal of Hematology. 91:467-472 |
ISSN: | 0361-8609 |
Popis: | Autologous blood transfusion (ABT) is an efficient way to increase sport performance. It is also the most challenging doping method to detect. At present, individual follow-up of haematological variables via the athlete biological passport (ABP) is used to detect it. Quantification of a novel hepatic peptide called hepcidin may be a new alternative to detect ABT. In this prospective clinical trial, healthy subjects received a saline injection for the control phase, after which they donated blood that was stored and then transfused 36 days later. The impact of ABT on hepcidin as well as haematological parameters, iron metabolism, and inflammation markers was investigated. Blood transfusion had a particularly marked effect on hepcidin concentrations compared to the other biomarkers, which included haematological variables. Hepcidin concentrations increased significantly: 12 hr and 1 day after blood reinfusion, these concentrations rose by seven- and fourfold, respectively. No significant change was observed in the control phase. Hepcidin quantification is a cost-effective strategy that could be used in an "ironomics" strategy to improve the detection of ABT. |
Databáze: | OpenAIRE |
Externí odkaz: |